Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433439 | 1.00 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL29386766 | 1.00 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL12857733 | 0.95 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL5833103 | 0.94 | CXCR3 (0.89) | CXCR3CYP3A4 | |
| SCHEMBL27015148 | 0.94 | CXCR3 (0.89) | CXCR3CYP3A4 | |
| SCHEMBL27015149 | 0.93 | CXCR3 (0.87) | CXCR3CYP3A4 | |
| SCHEMBL14960668 | 0.91 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL12857869 | 0.89 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL13770583 | 0.89 | CXCR3 (1.00) | CXCR3CYP3A4 | |
| SCHEMBL15064525 | 0.88 | CXCR3 (1.00) | CXCR3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238830-A2 | TARGETING INFILTRATING CD8+ T CELLS IN ALZHEIMER'S DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2024-11-21 | — | — | WO | claimed |
| CN-116144752-A | Drug target spot for relieving intestinal epithelial cell structural damage, activating intestinal epithelial cell autophagy and/or reducing intestinal inflammation and application | 华中农业大学 | 2023-05-23 | — | — | CN | claimed |
| US-20130172370-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF GLAUCOMA | VT IDIRECT ,INC. (US) | 2013-07-04 | — | — | US | claimed |
| CN-120114594-A | Application of CXCL11 inhibitor in preparation of medicine for enhancing curative effect of PD-1/PD-L1 monoclonal antibody on treating hepatocellular carcinoma | 大连医科大学 | 2025-06-10 | — | — | CN | disclosed |
| WO-2024238830-A2 | TARGETING INFILTRATING CD8+ T CELLS IN ALZHEIMER'S DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-118845785-A | Application of CXCR3 inhibitor in treating myocardial hypertrophy and heart failure induced by immune checkpoint inhibitor | 哈尔滨医科大学 | 2024-10-29 | — | — | CN | disclosed |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | Accencio LLC | 2024-01-18 | — | — | US | disclosed |
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093451-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2007150016-A2 | IL-8 RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007124424-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124423-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249672-A1 | IL-8 Receptor Antagonists | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-20070249672-A1 | IL-8 Receptor Antagonists | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-20070249672-A1 | IL-8 Receptor Antagonists | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321063-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | CXCR3, MTOR, CX3CR1 | CXCR3 1/4885CYP3A4 4721/4885 |
| US-20070249672-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR3 15/4885CYP3A4 3211/4885 |
| US-20240016813-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | CXCR3 963/4885CYP3A4 1847/4885 |
| US-20130172370-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF GLAUCOMA | CXCR3, CCR5, CCR7 | CXCR3 1/4885CYP3A4 3600/4885 |
| US-20090093451-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | CXCR3 15/4885CYP3A4 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.